The biggest research on Lassa fever prevalence in West Africa, run on $26 million funding, has been inaugurated with a focus on tracking the exact scale of prevalence and applying the data to boost the potential of a vaccine.
The Coalition for Epidemic Preparedness Innovations (CEPI) and the Nige
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
